RE: IFNB and corticosteroids29 Jan 2022 10:37
Luck , I like your shipbuilding analogy - very apt . lets hope it's not the Titanic !
The other trial P2 hospitalised data actually had a few more steroid patients on the drug side than on placebo , so definitely not an issue there .
Timing of delivery is also key . We have been trialing in the past with late stage intervention ( ie when patient in already intubed or on mechanical ventilation ) . Now we are looking at early stage treatment , before ICU on admittance to hospital .
The other trial believes the benefit is best when given at the start of serious conditions - ie when the fire flares up . Insert the IFN B to the lung cells , and let them fight the fire . That should stand for our drug too . We just get the fire engine to the scene via different route .
The subcutaneous route was ruled out as ineffective as the levels of IFNB reaching the lungs via that route was woeful .
Faron have clear evidence of this , and even published a paper . WHO ignored this evidence , as Merck were desperate to try and get some sort of positive outcome for their MS drug.
The SNG data will appear long before ours , but even if its great , it shouldn't put us out of the running . If anything , it may accelerate things as Interferon beta becomes global news .
But stepping away from Covid for a minute , Traumakine was being targeted at ARDs patients , often whose lungs were beyond the ability to inhale a nebulised treatment effectively ( ie the epithelial layers are flooded ), and post hoc analysis proved it works ( on INTEREST P3 trial) , just so long as those patients aren't on steroids .
It was also being developed as a general organ trauma drug for combat injuries . This is where we may see further news , as despite the D of D financing Hibiscus , it's not testing the area of therapy that they were originally interested in .
The use of steroids has just knackered our speed of progress for now .
I reckon there is still plenty going on with Traumakine development in the background , its just that Bex is getting all the limelight at present.
Sign In
Follow the stocks
